Logo image of LXEO

LEXEO THERAPEUTICS INC (LXEO) Stock Fundamental Analysis

NASDAQ:LXEO - Nasdaq - US52886X1072 - Common Stock - Currency: USD

3.89  -0.14 (-3.47%)

After market: 3.89 0 (0%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to LXEO. LXEO was compared to 571 industry peers in the Biotechnology industry. The financial health of LXEO is average, but there are quite some concerns on its profitability. LXEO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year LXEO has reported negative net income.
LXEO had a negative operating cash flow in the past year.
LXEO Yearly Net Income VS EBIT VS OCF VS FCFLXEO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

LXEO has a Return On Assets (-40.21%) which is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -46.81%, LXEO is in the better half of the industry, outperforming 67.85% of the companies in the same industry.
Industry RankSector Rank
ROA -40.21%
ROE -46.81%
ROIC N/A
ROA(3y)-48.51%
ROA(5y)N/A
ROE(3y)-59.94%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LXEO Yearly ROA, ROE, ROICLXEO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 -20 -40 -60 -80

1.3 Margins

LXEO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LXEO Yearly Profit, Operating, Gross MarginsLXEO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 -2K -4K -6K -8K

More info and screens

4

2. Health

2.1 Basic Checks

LXEO does not have a ROIC to compare to the WACC, probably because it is not profitable.
LXEO has more shares outstanding than it did 1 year ago.
The debt/assets ratio for LXEO has been reduced compared to a year ago.
LXEO Yearly Shares OutstandingLXEO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 5M 10M 15M 20M 25M
LXEO Yearly Total Debt VS Total AssetsLXEO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of 0.89, we must say that LXEO is in the distress zone and has some risk of bankruptcy.
LXEO has a better Altman-Z score (0.89) than 65.72% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that LXEO is not too dependend on debt financing.
LXEO has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: LXEO outperforms 43.69% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 0.89
ROIC/WACCN/A
WACC9.43%
LXEO Yearly LT Debt VS Equity VS FCFLXEO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

LXEO has a Current Ratio of 9.38. This indicates that LXEO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 9.38, LXEO is in the better half of the industry, outperforming 77.98% of the companies in the same industry.
LXEO has a Quick Ratio of 9.38. This indicates that LXEO is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of LXEO (9.38) is better than 78.15% of its industry peers.
Industry RankSector Rank
Current Ratio 9.38
Quick Ratio 9.38
LXEO Yearly Current Assets VS Current LiabilitesLXEO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for LXEO have decreased strongly by -12.14% in the last year.
Looking at the last year, LXEO shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)-12.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.17%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 5.47% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y22.84%
EPS Next 2Y12.07%
EPS Next 3Y7.08%
EPS Next 5Y5.47%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LXEO Yearly Revenue VS EstimatesLXEO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B 2.5B
LXEO Yearly EPS VS EstimatesLXEO Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LXEO. In the last year negative earnings were reported.
Also next year LXEO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LXEO Price Earnings VS Forward Price EarningsLXEO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LXEO Per share dataLXEO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.07%
EPS Next 3Y7.08%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LXEO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LEXEO THERAPEUTICS INC

NASDAQ:LXEO (2/21/2025, 8:00:00 PM)

After market: 3.89 0 (0%)

3.89

-0.14 (-3.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/bmo
Earnings (Next)03-17 2025-03-17/bmo
Inst Owners103.17%
Inst Owner Change0.11%
Ins Owners1.35%
Ins Owner Change6.69%
Market Cap128.64M
Analysts86.15
Price Target22.73 (484.32%)
Short Float %6.02%
Short Ratio7.34
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.45%
Min EPS beat(2)1.64%
Max EPS beat(2)9.25%
EPS beat(4)2
Avg EPS beat(4)-92.52%
Min EPS beat(4)-366.42%
Max EPS beat(4)9.25%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-0.64%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-12.81%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.78
P/tB 0.78
EV/EBITDA N/A
EPS(TTM)-14.62
EYN/A
EPS(NY)-3.07
Fwd EYN/A
FCF(TTM)-1.92
FCFYN/A
OCF(TTM)-1.9
OCFYN/A
SpS0
BVpS4.99
TBVpS4.99
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -40.21%
ROE -46.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.51%
ROA(5y)N/A
ROE(3y)-59.94%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 85.35%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.38
Quick Ratio 9.38
Altman-Z 0.89
F-Score4
WACC9.43%
ROIC/WACCN/A
Cap/Depr(3y)753.98%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.17%
EPS Next Y22.84%
EPS Next 2Y12.07%
EPS Next 3Y7.08%
EPS Next 5Y5.47%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-13.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-40.43%
EBIT Next 3Y-3.96%
EBIT Next 5YN/A
FCF growth 1Y-7.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-9.05%
OCF growth 3YN/A
OCF growth 5YN/A